Literature DB >> 22036046

Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz.

Nadia Leticee1, Jean-Paul Viard, Amina Yamgnane, Marina Karmochkine, Alexandra Benachi.   

Abstract

Contraception for HIV-positive women is a complex issue. Although the use of condoms is recommended, complementary methods of contraception are often prescribed. Antiretroviral therapy can lead to drug interactions and modify the efficacy of hormonal contraception. Two unintended pregnancies suggest that etonogestrel implants should be used with caution in patients on efavirenz. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22036046     DOI： 10.1016/j.contraception.2011.09.005

Source DB:  PubMed          Journal:  Contraception        ISSN： 0010-7824            Impact factor:   3.375


  21 in total

1.  Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.

Authors:  Megan Neary; Catherine A Chappell; Kimberly K Scarsi; Shadia Nakalema; Joshua Matovu; Sharon L Achilles; Beatrice A Chen; Marco Siccardi; Andrew Owen; Mohammed Lamorde
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

2.  Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.

Authors:  Catherine A Chappell; Mohammed Lamorde; Shadia Nakalema; Beatrice A Chen; Hope Mackline; Sharon A Riddler; Susan E Cohn; Kristin M Darin; Sharon L Achilles; Kimberly K Scarsi
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

3.  A systematic review of contraceptive continuation among women living with HIV.

Authors:  Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones
Journal:  Contraception       Date:  2018-02-09       Impact factor: 3.375

Review 4.  Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.

Authors:  Andrea R Thurman; Sharon Anderson; Gustavo F Doncel
Journal:  Am J Reprod Immunol       Date:  2014-02-13       Impact factor: 3.886

Review 5.  Contraception for HIV-Infected Adolescents.

Authors:  Athena P Kourtis; Ayesha Mirza
Journal:  Pediatrics       Date:  2016-09       Impact factor: 7.124

6.  Medical eligibility, contraceptive choice, and intrauterine device acceptance among HIV-infected women receiving antiretroviral therapy in Lilongwe, Malawi.

Authors:  Lisa B Haddad; Caryl Feldacker; Denise J Jamieson; Hannock Tweya; Carrie Cwiak; Amy G Bryant; Mina C Hosseinipour; Thomas Chaweza; Linly Mlundira; Fanny Kachale; Gretchen S Stuart; Irving Hoffman; Sam Phiri
Journal:  Int J Gynaecol Obstet       Date:  2014-05-13       Impact factor: 3.561

7.  Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy.

Authors:  Maria Pyra; Renee Heffron; Nelly R Mugo; Kavita Nanda; Katherine K Thomas; Connie Celum; Athena P Kourtis; Edwin Were; Helen Rees; Elizabeth Bukusi; Jared M Baeten
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

8.  Immediate Postpartum Intrauterine Device in HIV-Infected Women: Experience from a Tertiary Care Center in Côte d'Ivoire.

Authors:  Edouard N'guessan; Franck Gbeli; Jean-Marc Dia; Privat Guie; Nguessan Kouame Roseline
Journal:  J Obstet Gynaecol India       Date:  2019-10-18

9.  Thai national guidelines for the prevention of mother-to-child transmission of human immunodeficiency virus 2017.

Authors:  Rangsima Lolekha; Kulkanya Chokephaibulkit; Nittaya Phanuphak; Surasith Chaithongwongwatthana; Sasisopin Kiertiburanakul; Pleonchan Chetchotisakd; Sarawut Boonsuk
Journal:  Asian Biomed (Res Rev News)       Date:  2017-04

10.  Effect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: a prospective cohort study in Kenya.

Authors:  David Hubacher; Jennifer Liku; James Kiarie; Joel Rakwar; Peter Muiruri; Jackline Omwenga; Pai-Lien Chen
Journal:  J Int AIDS Soc       Date:  2013-03-01       Impact factor: 5.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.